🕵️ Prelude Therapeutics Inc ($PRLD)
SEC insider & ownership activity, last 12 months · CIK 1678660 · every row links its SEC filing
Over the last 12 months insiders bought $35.0M with no open-market selling against it. Orbimed Advisors LLC bought $12.5M in discretionary trades (Apr). Baker BROS. Advisors LP trimmed 23.5% → 15.5%; Baker BROS. Advisors (GP) LLC trimmed 23.5% → 15.5%. No red-flag 8-Ks in the window.
Monthly net open-market insider flow, last 12 months (up = net buying)
Insider flow
3 buyers, $35.0M (6 lots) · 0 sellers, $0 (0 lots)
| Insider | Buys | Bought | Sells | Sold | Last |
|---|---|---|---|---|---|
| Orbimed Advisors LLC | 2 | $12.5M | 0 | – | Apr 21, 2026 |
| David P. Bonita | 2 | $12.5M | 0 | – | Apr 21, 2026 |
| Baker BROS. Advisors LP | 2 | $10.0M | 0 | – | Apr 21, 2026 |
5%+ holders
| Holder | Stake | Class | Schedule | Event | |
|---|---|---|---|---|---|
| Orbimed Advisors LLC | 16.0% | 13D | Apr 21, 2026 | filing ↗ | |
| Baker BROS. Advisors LP | 15.5% | 13D | Apr 20, 2026 | filing ↗ | |
| Baker BROS. Advisors (GP) LLC | 15.5% | 13D | Apr 20, 2026 | filing ↗ | |
| Julian C. Baker | 15.5% | 13D | Apr 20, 2026 | filing ↗ | |
| Felix J. Baker | 15.5% | 13D | Apr 20, 2026 | filing ↗ | |
| Orbimed Capital GP VI LLC | 14.6% | 13D | Apr 21, 2026 | filing ↗ | |
| Vaddi Krishna | 13.2% | 13G | Feb 13, 2026 | filing ↗ | |
| RA Capital Management, L.P. | 9.9% | 13G | Apr 28, 2026 | filing ↗ | |
| Peter Kolchinsky | 9.9% | 13G | Apr 28, 2026 | filing ↗ | |
| Rajeev Shah | 9.9% | 13G | Apr 28, 2026 | filing ↗ | |
| RA Capital Healthcare Fund, L.P. | 9.9% | 13G | Apr 28, 2026 | filing ↗ | |
| Incyte Corp | 9.9% | 13G | Nov 7, 2025 | filing ↗ | |
| Soleus Capital Management, L.P. | 5.2% | 13G | Jul 8, 2026 | filing ↗ | |
| Soleus GP, LLC | 5.2% | 13G | Jul 8, 2026 | filing ↗ | |
| Levy Guy | 5.2% | 13G | Jul 8, 2026 | filing ↗ | |
| Soleus Capital Master Fund, L.P. | exited | 13G | Jul 8, 2026 | filing ↗ | |
| Soleus Capital, LLC | exited | 13G | Jul 8, 2026 | filing ↗ | |
| Soleus Capital Group, LLC | exited | 13G | Jul 8, 2026 | filing ↗ | |
| Soleus Private Equity Fund III, L.P. | exited | 13G | Jul 8, 2026 | filing ↗ | |
| Soleus Private Equity GP III, LLC | exited | 13G | Jul 8, 2026 | filing ↗ | |
| Soleus PE GP III, LLC | exited | 13G | Jul 8, 2026 | filing ↗ |
Planned insider sales (Form 144)
No sale notices filed in the last 12 months.
Material events (8-K)
| Item | Event date | |
|---|---|---|
| Shareholder vote (5.07) | Jun 9, 2026 | filing ↗ |
| Earnings (2.02) | May 12, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | May 12, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | May 12, 2026 | filing ↗ |
| Material agreement (1.01) | Apr 20, 2026 | filing ↗ |
| Other events (8.01) | Apr 20, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Apr 20, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Apr 20, 2026 | filing ↗ |
| Other events (8.01) | Apr 20, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Apr 20, 2026 | filing ↗ |
| Officer/director changes (5.02) | Apr 15, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Apr 15, 2026 | filing ↗ |
| Other events (8.01) | Mar 12, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Mar 12, 2026 | filing ↗ |
| Earnings (2.02) | Mar 10, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Mar 10, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Mar 10, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Jan 29, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jan 29, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Jan 9, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jan 9, 2026 | filing ↗ |
| Earnings (2.02) | Nov 12, 2025 | filing ↗ |
| Reg FD disclosure (7.01) | Nov 12, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Nov 12, 2025 | filing ↗ |
| Material agreement (1.01) | Nov 3, 2025 | filing ↗ |
| Unregistered equity sale (3.02) | Nov 3, 2025 | filing ↗ |
| Officer/director changes (5.02) | Nov 3, 2025 | filing ↗ |
| Reg FD disclosure (7.01) | Nov 3, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Nov 3, 2025 | filing ↗ |
| Officer/director changes (5.02) | Oct 15, 2025 | filing ↗ |